Alteminostat, with the CAS number 1246374-97-9, is a small molecule that functions primarily as a histone deacetylase (HDAC) inhibitor. It is characterized by its ability to modulate gene expression by altering the acetylation status of histones, which can lead to changes in chromatin structure and function. This compound has been investigated for its potential therapeutic applications, particularly in the treatment of various cancers, as it can induce cell cycle arrest, apoptosis, and differentiation in cancer cells. Alteminostat exhibits selectivity for certain HDAC isoforms, which may contribute to its efficacy and safety profile. Additionally, it has been studied in combination with other therapies to enhance anti-tumor effects. The compound is typically administered in a clinical setting and is subject to ongoing research to better understand its pharmacodynamics, pharmacokinetics, and overall impact on cancer treatment regimens. As with many HDAC inhibitors, its use may be associated with side effects, necessitating careful monitoring during therapy.

Alteminostat

1246374-97-9: Alteminostat, with the CAS number 1246374-97-9, is a small molecule that functions primarily as a histone deacetylase (HDAC) inhibitor. It is characterized by its ability to modulate gene expression by altering the acetylation status of histones, which can lead to changes in chromatin structure and function. This compound has been investigated for its potential therapeutic applications, particularly in the treatment of various cancers, as it can induce cell cycle arrest, apoptosis, and differentiation in cancer cells. Alteminostat exhibits selectivity for certain HDAC isoforms, which may contribute to its efficacy and safety profile. Additionally, it has been studied in combination with other therapies to enhance anti-tumor effects. The compound is typically administered in a clinical setting and is subject to ongoing research to better understand its pharmacodynamics, pharmacokinetics, and overall impact on cancer treatment regimens. As with many HDAC inhibitors, its use may be associated with side effects, necessitating careful monitoring during therapy.

<p>Alteminostat is used as a histone deacetylase inhibitor and is an antineoplastic drug candidate.</p>

CAS 1246374-97-9

Alteminostat

Alteminostat

Ref: TM-T25059